Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 6/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL3860163 | 1.00 | GSK3B (0.38) | GSK3BBCHEPPARGALDH1A1SMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL4411335 | 1.00 | GSK3B (0.38) | GSK3BBCHEPPARGALDH1A1SMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL28099769 | 1.00 | GSK3B (0.38) | GSK3BBCHEPPARGALDH1A1SMN1; SMN2 | |
| SCHEMBL29366806 | 0.98 | GSK3B (0.38) | GSK3BBCHEPPARGALDH1A1SMN1; SMN2 | |
| SCHEMBL378842 | 0.98 | GSK3B (0.38) | GSK3BBCHEPPARGALDH1A1SMN1; SMN2 | |
| SCHEMBL15876008 | 0.78 | AVPR2 (0.31) | GSK3BBCHEKMT2A | |
| SCHEMBL21647910 | 0.77 | BCHE (0.37) | GSK3BBCHEPPARGALDH1A1SMN1; SMN2 | |
| SCHEMBL3952904 | 0.77 | CRHBP (0.35) | — | |
| SCHEMBL10481670 | 0.75 | — | — | |
| SCHEMBL8342783 | 0.73 | ALDH1A1 (0.35) | GSK3BBCHEPPARGALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325643-A1 | BINDING AGENTS CAPABLE OF BINDING TO CD27 IN COMBINATION THERAPY | GENMAB AS (DK) | 2025-10-23 | — | — | US | disclosed |
| US-20250289900-A1 | ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOF | GENMAB AS (DK) | 2025-09-18 | — | — | US | disclosed |
| US-20250289899-A1 | ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOF | GENMAB AS (DK) | 2025-09-18 | — | — | US | disclosed |
| CN-120078676-A | Preparation of guava and vitreous factor essence | 广西民族大学 | 2025-06-03 | — | — | CN | disclosed |
| EP-4522275-A1 | BINDING AGENTS CAPABLE OF BINDING TO CD27 IN COMBINATION THERAPY | Genmab A/S (DK) | 2025-03-19 | — | — | EP | disclosed |
| EP-4522657-A1 | BINDING AGENTS CAPABLE OF BINDING TO CD27 IN COMBINATION THERAPY | Genmab A/S (DK) | 2025-03-19 | — | — | EP | disclosed |
| CN-119451985-A | Binding agents capable of binding CD27 in combination therapies | 健玛保 | 2025-02-14 | — | — | CN | disclosed |
| CN-119365215-A | Binding agents capable of binding CD27 in combination therapies | 健玛保 | 2025-01-24 | — | — | CN | disclosed |
| EP-4399227-A1 | ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOF | Genmab A/S (DK) | 2024-07-17 | — | — | EP | disclosed |
| CN-118055950-A | Antibodies capable of binding CD27, variants thereof and uses thereof | 健玛保 | 2024-05-17 | — | — | CN | disclosed |
| WO-2023218051-A1 | BINDING AGENTS CAPABLE OF BINDING TO CD27 IN COMBINATION THERAPY | GENMAB A/S (DK) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023218046-A1 | BINDING AGENTS CAPABLE OF BINDING TO CD27 IN COMBINATION THERAPY | GENMAB A/S (DK) | 2023-11-16 | — | — | WO | disclosed |
| US-20230212301-A1 | ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOF | GENMAB A/S (DK) | 2023-07-06 | — | — | US | disclosed |
| US-20230109496-A1 | ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOF | GENMAB A/S (DK) | 2023-04-06 | — | — | US | disclosed |
| WO-2023031473-A1 | ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOF | GENMAB B.V. (NL) | 2023-03-09 | — | — | WO | disclosed |